• Cancer
• Eliminating cervical cancer: Promising developments in primary prevention

  Cancer

  Thu Sep 26, 2019 12:00
• Cancer Biology & Therapy: Table of Contents: Taylor and Francis
• A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement

  .

  Cancer Biology & Therapy: Table of Contents: Taylor and Francis

  Fri Sep 27, 2019 02:25
• BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment

  .

  Cancer Biology & Therapy: Table of Contents: Taylor and Francis

  Fri Sep 27, 2019 02:19
• Cancer Biotherapy & Radiopharmaceuticals - Table of Contents
• Role of Diffusional Kurtosis Imaging in Evaluating the Efficacy of Transcatheter Arterial Chemoembolization in Patients with Liver Cancer

  Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.

  Cancer Biotherapy & Radiopharmaceuticals - Table of Contents

  Fri Sep 27, 2019 00:00
• Cancer Immunology, Immunotherapy
• PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor

  Abstract It has been shown that protein tyrosine phosphatase non-receptor type (PTPN) 3 inhibits T-cell activation. However, there is no definitive conclusion about how the inhibition of PTPN3 in lymphocytes affects immune functions in human lymphocytes. In the present study, we showed that PTPN3 inhibition significantly contributes to the enhanced activation of activated human lymphocytes. The PTPN3 expression of lymphocytes w

  Cancer Immunology, Immunotherapy

  Thu Sep 26, 2019 17:00
• Cancers
• Cancers, Vol. 11, Pages 1460: Glucose Metabolism in Pancreatic Cancer

  Cancers, Vol. 11, Pages 1460: Glucose Metabolism in Pancreatic Cancer Cancers doi: 10.3390/cancers11101460 Authors: Liang Yan Priyank Raj Wantong Yao Haoqiang Ying Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers, with a five-year survival rate of around 5% to 8%. To date, very few available drugs have been successfully used to treat PDAC due to the poor understanding of the tumor-spec

  Cancers

  Sat Sep 28, 2019 17:00
• Cancers, Vol. 11, Pages 1462: FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications

  Cancers, Vol. 11, Pages 1462: FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications Cancers doi: 10.3390/cancers11101462 Authors: José L Marín-Rubio Laura Vela-Martín José Fernández-Piqueras María Villa-Morales FADD was initially described as an adaptor molecule for death receptor-mediated apoptosis, but subsequently it has been implicated in nonapoptotic cellular processes such as prolifer

  Cancers

  Sat Sep 28, 2019 17:00
• Cancers, Vol. 11, Pages 1461: Arl13b Regulates Breast Cancer Cell Migration and Invasion by Controlling Integrin-Mediated Signaling

  Cancers, Vol. 11, Pages 1461: Arl13b Regulates Breast Cancer Cell Migration and Invasion by Controlling Integrin-Mediated Signaling Cancers doi: 10.3390/cancers11101461 Authors: Cristina Casalou Alexandra Faustino Fernanda Silva Inês C. Ferreira Daniela Vaqueirinho Andreia Ferreira Pedro Castanheira Teresa Barona José S. Ramalho Jacinta Serpa Ana Félix Duarte C. Barral Breast cancer is the first cause

  Cancers

  Sat Sep 28, 2019 17:00
• Cancers, Vol. 11, Pages 1459: P120 Catenin Isoforms Differentially Associate with Breast Cancer Invasion and Metastasis

  Cancers, Vol. 11, Pages 1459: P120 Catenin Isoforms Differentially Associate with Breast Cancer Invasion and Metastasis Cancers doi: 10.3390/cancers11101459 Authors: Jan-Hendrik Venhuizen Paul N. Span Koen van den Dries Sebastian Sommer Peter Friedl Mirjam M. Zegers Tumor metastasis is the endpoint of tumor progression and depends on the ability of tumor cells to locally invade tissue, transit through the bloodstream a

  Cancers

  Sat Sep 28, 2019 17:00
• Cancers, Vol. 11, Pages 1463: Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer

  Cancers, Vol. 11, Pages 1463: Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer Cancers doi: 10.3390/cancers11101463 Authors: Marie Joelle Jabagi Anthony Goncalves Norbert Vey Thien Le Tri Mahmoud Zureik Rosemary Dray-Spira An indirect consequence of the improved long-term survival seen in patients with breast cancer (BC) is the increased risk of hematologic malignant neoplasms (HM)

  Cancers

  Sat Sep 28, 2019 17:00
• Cancers, Vol. 11, Pages 1458: PTEN and Gynecological Cancers

  Cancers, Vol. 11, Pages 1458: PTEN and Gynecological Cancers Cancers doi: 10.3390/cancers11101458 Authors: Camilla Nero Francesca Ciccarone Antonella Pietragalla Giovanni Scambia PTEN is a tumour suppressor gene, and its loss of function is frequently observed in both heritable and sporadic cancers. It is involved in a great variety of biological processes, including maintenance of genomic stability, cell survival, migration

  Cancers

  Fri Sep 27, 2019 17:00
• Cancers, Vol. 11, Pages 1455: Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia

  Cancers, Vol. 11, Pages 1455: Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia Cancers doi: 10.3390/cancers11101455 Authors: Federico Lussana Chiara Caprioli Paola Stefanoni Chiara Pavoni Orietta Spinelli Ksenija Buklijas Anna Michelato GianMaria Borleri Alessandra Algarot

  Cancers

  Fri Sep 27, 2019 17:00
• Cancers, Vol. 11, Pages 1456: N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor

  Cancers, Vol. 11, Pages 1456: N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor Cancers doi: 10.3390/cancers11101456 Authors: Donatella Fiore Chiara Piscopo Maria Chiara Proto Michele Vasaturo Fabrizio Dal Piaz Bruno Marcello Fusco Cristina Pagano Chiara Laezza Maurizio Bifulco Patrizia Gazzerro N6-isopentenyladenosine has been sho

  Cancers

  Fri Sep 27, 2019 17:00
• Cancers, Vol. 11, Pages 1454: A Functional Analysis of the Unclassified Pro2767Ser BRCA2 Variant Reveals Its Potential Pathogenicity that Acts by Hampering DNA Binding and Homology-Mediated DNA Repair

  Cancers, Vol. 11, Pages 1454: A Functional Analysis of the Unclassified Pro2767Ser BRCA2 Variant Reveals Its Potential Pathogenicity that Acts by Hampering DNA Binding and Homology-Mediated DNA Repair Cancers doi: 10.3390/cancers11101454 Authors: Maria Valeria Esposito Giuseppina Minopoli Luciana Esposito Valeria D’Argenio Federica Di Maggio Emanuele Sasso Massimiliano D’Aiuto Nicola Zambrano Francesco Salvatore

  Cancers

  Fri Sep 27, 2019 17:00
• Cancers, Vol. 11, Pages 1457: c-Myc Acts as a Competing Endogenous RNA to Sponge miR-34a, in the Upregulation of CD44, in Urothelial Carcinoma

  Cancers, Vol. 11, Pages 1457: c-Myc Acts as a Competing Endogenous RNA to Sponge miR-34a, in the Upregulation of CD44, in Urothelial Carcinoma Cancers doi: 10.3390/cancers11101457 Authors: Pie-Che Chen Chih-Chia Yu Wen-Yu Huang Wan-Hong Huang Yu-Ming Chuang Ru-Inn Lin Jora M. J. Lin Hon-Yi Lin Yeong-Chin Jou Cheng-Huang Shen Michael W. Y. Chan MicroRNAs (miRNAs) have been shown to play a crucial role in

  Cancers

  Fri Sep 27, 2019 17:00
• Cancers, Vol. 11, Pages 1453: Diclofenac Potentiates Sorafenib-Based Treatments of Hepatocellular Carcinoma by Enhancing Oxidative Stress

  Cancers, Vol. 11, Pages 1453: Diclofenac Potentiates Sorafenib-Based Treatments of Hepatocellular Carcinoma by Enhancing Oxidative Stress Cancers doi: 10.3390/cancers11101453 Authors: Duval Troquier de Souza Silva Demartines Dormond Sorafenib is the first developed systemic treatment for advanced forms of hepatocellular carcinoma, which constitutes the most frequent form of primary liver cancers and is a major global

  Cancers

  Thu Sep 26, 2019 17:00
• Cancers, Vol. 11, Pages 1452: A Network Analysis of Multiple Myeloma Related Gene Signatures

  Cancers, Vol. 11, Pages 1452: A Network Analysis of Multiple Myeloma Related Gene Signatures Cancers doi: 10.3390/cancers11101452 Authors: Yu Liu Haocheng Yu Seungyeul Yoo Eunjee Lee Alessandro Laganà Samir Parekh Eric E. Schadt Li Wang Jun Zhu Multiple myeloma (MM) is the second most prevalent hematological cancer. MM is a complex and heterogeneous disease, and thus, it is essential to leverage omics data fro

  Cancers

  Thu Sep 26, 2019 17:00
• Cancers, Vol. 11, Pages 1451: Adipocytes and microRNAs Crosstalk: A Key Tile in the Mosaic of Breast Cancer Microenvironment

  Cancers, Vol. 11, Pages 1451: Adipocytes and microRNAs Crosstalk: A Key Tile in the Mosaic of Breast Cancer Microenvironment Cancers doi: 10.3390/cancers11101451 Authors: Erika Bandini Tania Rossi Giulia Gallerani Francesco Fabbri Breast cancer (BC) is a disease characterized by a high grade of heterogeneity. Consequently, despite the great achievements obtained in the last decades, most of the current therapeutic regimens s

  Cancers

  Thu Sep 26, 2019 17:00
• Cancers, Vol. 11, Pages 1449: Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study

  Cancers, Vol. 11, Pages 1449: Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study Cancers doi: 10.3390/cancers11101449 Authors: Mariantonia Logozzi Daniela F. Angelini Alessandro Giuliani Davide Mizzoni Rossella Di Raimo Martina Maggi Alessandro Gentilucci Vittorio Marzio Stefano Salciccia Giovanna Borsellino Luca Bat

  Cancers

  Thu Sep 26, 2019 17:00
• Cancers, Vol. 11, Pages 1450: Experimental Models to Define the Genetic Predisposition to Liver Cancer

  Cancers, Vol. 11, Pages 1450: Experimental Models to Define the Genetic Predisposition to Liver Cancer Cancers doi: 10.3390/cancers11101450 Authors: Rosa M. Pascale Maria M. Simile Graziella Peitta Maria A. Seddaiu Francesco Feo Diego F. Calvisi Hepatocellular carcinoma (HCC) is a frequent human cancer and the most frequent liver tumor. The study of genetic mechanisms of the inherited predisposition to HCC, implicating

  Cancers

  Thu Sep 26, 2019 17:00
• Cancers, Vol. 11, Pages 1448: STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases

  Cancers, Vol. 11, Pages 1448: STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases Cancers doi: 10.3390/cancers11101448 Authors: Stella Logotheti Brigitte M. Pützer Melanoma is a skin cancer which can become metastatic, drug-refractory, and lethal if managed late or inappropriately. An increasing number of melanoma patients exhibits autoimmune diseases, either as pre-existing conditions or as s

  Cancers

  Thu Sep 26, 2019 17:00
• Clinical and translational oncology
• The utilization of saliva as an early diagnostic tool for oral cancer: microRNA as a biomarker

  Abstract Recently, dentistry presents a preventive philosophy, seeking early diagnoses and minimally traumatic treatments for patients. Cancer is known for its aggressive nature, where its signals and symptoms may only appear in advanced stages of the disease, therefore, reducing the possibility of using atraumatic treatment options and patient survival. Saliva has in its composition substances which can be used as biomarkers f

  Clinical and translational oncology

  Thu Sep 26, 2019 17:00
• Clinical and Translational Science
• Effect of Genetic and Non‐genetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure

  Abstract This prospective cohort study evaluated the association between renin‐angiotensin‐aldosterone‐system genotypes and response to spironolactone in 155 Egyptian patients with heart failure with reduced ejection fraction (HFrEF). Genotype frequencies for AGT rs699 were: CC=16%, CT=48%, and TT=36%. Frequencies for CYP11B2 rs1799998 were: TT=33%, TC=50%, and CC=17%. After six months of spironolactone treatment, change in left ventricular ejec

  Clinical and Translational Science

  Fri Sep 27, 2019 07:26
• Clinical Cancer Research Online First Articles
• Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers

  Purpose: Anti-programmed death-1 (PD-1) receptor-based therapeutics improve survival in recurrent head and neck squamous cell carcinoma (HNSCC) patients but many do not benefit due to a low response rate. Herein, we identified EZH2 as a therapeutic target that enhanced tumor cell antigen presentation and subsequently sensitized resistant tumors to anti-PD-1 therapy. Experimental Design: EZH2 regulation of antigen presentation was defined using

  Clinical Cancer Research Online First Articles

  Fri Sep 27, 2019 06:52
• DNA methylation profiling identifies distinct clusters in angiosarcomas.

  Purpose: DNA methylation profiling has previously uncovered biologically and clinically meaningful subgroups within many tumor types, but was not yet performed in angiosarcoma (AS). AS is a rare sarcoma with very heterogeneous clinical presentations, which may be based on differences in biological background. In this exploratory study, DNA methylation profiling of 36 primary AS samples from visceral, deep soft tissue (ST), radiation-induced (RT)

  Clinical Cancer Research Online First Articles

  Fri Sep 27, 2019 06:52
• Today's special on the anticancer menu: immunomodulation by antifolates

  Pemetrexed is widely employed for the clinical management of mesothelioma and non-small cell lung carcinoma, largely based on its ability to curtail folate metabolism in highly proliferating cells. Recent preclinical findings suggest that the therapeutic efficacy of pemetrexed may involve an unsuspected immunological component.

  Clinical Cancer Research Online First Articles

  Fri Sep 27, 2019 06:52
• Critical Reviews in Oncology/Hematology (open access)
• Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers

  Publication date: Available online 26 September 2019Source: Critical Reviews in Oncology/HematologyAuthor(s): Eleonora Rofi, Marzia Del Re, Elena Arrigoni, Mimma Rizzo, Lorenzo Fontanelli, Stefania Crucitta, Giulia Gianfilippo, Giuliana Restante, Stefano Fogli, Camillo Porta, Romano Danesi, Manuela SchmidingerAbstractChemotherapy is the reference treatment for patients with advanced urothelial carcinoma, both in the neo-adjuvant and adjuvant sett

  Critical Reviews in Oncology/Hematology (open access)

  Fri Sep 27, 2019 05:22
• Future Oncology
• Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia

  Future Oncology, Ahead of Print.

  Future Oncology

  Fri Sep 27, 2019 03:07
• Future Oncology.
• Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia.

  Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia. Future Oncol. 2019 Sep 27;: Authors: Paul S, DiPippo AJ, Ravandi F, Kadia TM Abstract Fms-like tyrosine kinase 3 (FLT3) mutations, characterized by an internal-tandem duplication or missense mutations in the tyrosine kinase domain, are observed in a third of patients with newly diagnosed acute myeloid le

  Future Oncology.

  Sat Sep 28, 2019 12:52
• Medical Oncology
• SOX4 is activated by C-MYC in prostate cancer

  Abstract Although MYC proto-oncogene (C-MYC) amplification has been consistently reported to be a potential marker for prostate cancer (PCa) progression and prognosis, the clinicopathological and prognostic significance of C-MYC protein expression remains controversial. Overexpression of SOX4 has been shown to play important roles in multiple cancers including PCa. However, the link between these two critical genetic aberrati

  Medical Oncology

  Thu Sep 26, 2019 17:00
• Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells

  Abstract The vasoactive intestinal peptide receptor-1(VIPR1) has prominent growth effects on a number of common neoplasms. However, there were contradictions in the effect cross different cancers. We aimed to explore the effect of VIPR1 overexpression on a human lung adenocarcinoma cell line H1299. GEO dataset was used to screen differentially expressed genes in lung adenocarcinoma tissues. The expression of VIPR1 mRNA was de

  Medical Oncology

  Thu Sep 26, 2019 17:00
• Molecular Cancer Therapeutics Online First Articles
• Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer

  YAP and TAZ are central determinants of malignancy, however, their functions remain still undruggable. We identified TGFβ-activated kinase 1 (TAK1) as a central hub integrating the most relevant signals sustaining pancreatic cancer aggressiveness and chemoresistance. Glycogen synthase kinase (GSK)3 is known to stabilize TAK1, and its inhibition causes a reduction in TAK1 levels. Here, we hypothesized that TAK1 could sustain YAP/TAZ program, and t

  Molecular Cancer Therapeutics Online First Articles

  Fri Sep 27, 2019 07:24
• Quantitative high-throughput screening using an organotypic model identifies compounds that inhibit ovarian cancer metastasis.

  The tumor microenvironment (TME) is a key determinant of metastatic efficiency. We performed a quantitative high throughput screen (qHTS) of diverse medicinal-chemistry tractable scaffolds (44,420 compounds) and pharmacologically active small molecules (386 compounds) using a layered organotypic, robust assay representing the ovarian cancer (OvCa) metastatic TME. This 3D model contains primary human mesothelial cells, fibroblasts and extracellula

  Molecular Cancer Therapeutics Online First Articles

  Fri Sep 27, 2019 07:24
• Molecular Carcinogenesis
• Antiapoptotic properties of MALT1 protease are associated with redox homeostasis in ABC‐DLBCL cells

  Abstract Mucosa‐associated lymphoid tissue lymphoma translocation protein‐1 (MALT1) protease presents crucial antiapoptotic properties in activated B cell‐like diffuse large B‐cell lymphoma (ABC‐DLBCL); however, the mechanism is unclear. Here, we reported that inhibition of MALT1 protease in ABC‐DLBCL cells led to cell apoptosis, along with elevated mitochondrial reactive oxygen species production and a reduced oxygen consumption rate. These alt

  Molecular Carcinogenesis

  Thu Sep 26, 2019 08:31
• Radiotherapy and Oncology
• Access to radiotherapy and its association with cancer outcomes in a high-income country: Addressing the inequity in Canada

  Cancer is the leading cause of death and premature mortality in Canada [1]. Despite being a high-income country with a universal healthcare system, regional disparities in cancer outcomes persist. This may be related to poorer accessibility to cancer services, particularly for low-income populations, those residing in rural and/or remote areas, the elderly, and new immigrants [2]. Indeed, disparities in access to healthcare were recently highligh

  Radiotherapy and Oncology

  Fri Sep 27, 2019 17:00
• Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy

  Brachytherapy (BT) is widely used for salvage therapy in patients with biochemical failure (BF) after radiotherapy for prostate cancer (PCa). Although low-dose-rate (LDR) and high-dose-rate (HDR) BT are both used for salvage therapy, it is not clear whether there are any differences between these two approaches in terms of efficacy or toxicity in this setting. Therefore, we review the institutional experience of the members of the Urological Tumo

  Radiotherapy and Oncology

  Thu Sep 26, 2019 17:00
• ScienceDirect Publication: Cancer Epidemiology (open access)
• Food consumption, meat cooking methods and diet diversity and the risk of bladder cancer

  Publication date: December 2019Source: Cancer Epidemiology, Volume 63Author(s): Matteo Di Maso, Federica Turati, Cristina Bosetti, Maurizio Montella, Massimo Libra, Eva Negri, Monica Ferraroni, Carlo La Vecchia, Diego Serraino, Jerry PoleselAbstractBackgroundSince food metabolites are eliminated by the urinary tract, several studies have investigated the association between diet and bladder cancer risk. Recently, the World Cancer Research Fund In

  ScienceDirect Publication: Cancer Epidemiology (open access)

  Fri Sep 27, 2019 05:38
• Table of contents

  Publication date: October 2019Source: Cancer Epidemiology, Volume 62Author(s):

  ScienceDirect Publication: Cancer Epidemiology (open access)

  Fri Sep 27, 2019 05:38
• Title page / Editorial Board

  Publication date: October 2019Source: Cancer Epidemiology, Volume 62Author(s):

  ScienceDirect Publication: Cancer Epidemiology (open access)

  Fri Sep 27, 2019 05:38